A novel TNM staging system for gastric cancer based on the metro-ticket paradigm: a comparative study with the AJCC-TNM staging system

Abstract

Background The metro-ticket prognostic tool for hepatocellular carcinoma has been proven to predict outcome, but a similar concept has not been investigated for GC. The objective of the current study was to apply the principles of the metro-ticket paradigm to develop a novel TNM staging system (nTNM) for gastric cancer (GC). Methods The nTNM considered the distance from the origin on a Cartesian plane incorporating the pN (x-axis) and pT (y-axis) stages. GC patients undergoing radical resection at Fujian Medical University Union Hospital (FMUUH) (n = 4267) were included. The nTNM was validated using 2 external cohorts from the Sun Yat-sen University Cancer Center (SYSUCC) (n = 1800) and Surveillance, Epidemiology, and End Results (SEER) (n = 3227) databases. Results nTNM classes with the same distance from the origin have same stage; the stage increases with this distance. Among all patients, 48.0% (n = 2049) were restaged in the nTNM compared with the 7th edition of the AJCC-TNM classification; 26.2% (n = 1116) were downstaged in the nTNM compared with the 8th edition. The nTNM provides significant survival differences between stages (all P < 0.001). The survival difference between stages IB and IIA was especially large for the nTNM (P < 0.001) compared to the 7th and 8th editions (P = 0.073). The concordance index and hazard ratio increased successively with the nTNM stage. Similar findings were observed in both external cohorts. Conclusion Compared with the AJCC-TNM classification, the nTNM for GC is easier to remember and provides some improvements; therefore, the nTNM may be considered for adoption in future editions of the AJCC-TNM classification.Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The predictive value of the preoperative C-reactive protein–albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data

“…Adjuvant chemotherapy: according to the patient's wishes and their physical condition, fluoride-based adjuvant chemotherapy was recommended for most patients with pathological stage II and III disease [20] in our center, as previously described [21,22]. A total of 256 patients (63.8%) received adjuvant chemotherapy, with the median number of cycles being 5 (range 1-12), similar to a previous study [23].…”

A novel online prognostic tool to predict long‐term survival after liver resection for intrahepatic cholangiocarcinoma: The “metro‐ticket” paradigm

“…Sasaki et al recently applied the metro‐ticket concept using the maximum tumor size and number of lesions to define prognosis of patients undergoing resection for CRLM. In a different study, Lu et al developed a novel TNM staging system for gastric cancer based on the same principles. To date, however, no study has applied the metro‐ticket concept to patients undergoing surgery for ICC.…”

“…More recently, an updated HCC metro‐ticket system incorporated individual tumor characteristics (ie, tumor size and number) and alpha‐fetoprotein (AFP) levels . While the metro‐ticket approach has been applied to other malignancies such as colorectal liver metastases (CRLM) and gastric cancer, its applicability to ICC has never been investigated. As such, the objective of the current study was to apply the principles of the metro‐ticket paradigm to patients undergoing liver resection for ICC.…”

Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer

“…According to the Japanese Classification of Gastric Carcinoma, PAC with S-1 is recommended for GC patients with pathological stage II or III disease [17]. In our center, fluoride-assisted chemotherapy is also recommended for most stage II or III GC patients, depending on the patient’s wishes and physical condition [18]. In this cohort, 256 patients (63.8%) received 5-FU adjuvant chemotherapy with a median cycle of 5 (range 1–12), similar to a previous study [19].…”